The consensus one-year price target sits at $1,209.21, implying significant upside from the current price of $935.58. The analyst breakdown: 24 Buy ratings, 6 Hold, and just 1 Sell. Lilly's 2026 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The FDA approval of the GLP-1 ...

Foundayo, a new weight loss pill from Eli Lilly, is the first oral GLP-1 that doesn't require fasting. In clinical trials, people lost an average of 8-25 pounds on the drug. One man who took the pill ...

Eli Lilly, the Indianapolis-based pharmaceutical company, officially received approval from the Food and Drug Administration for a new weight-loss pill on April 1. The company shared in a press ...

The Food and Drug Administration granted expedited approval on Wednesday to Eli Lilly’s new weight-loss pill, a medication used to treat obesity and other weight-related conditions. Orforglipron is a ...

Eli Lilly opposes the White House's push to codify 'most favored nation' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies ...

The U.S. Food and Drug Administration on Wednesday gave its approval to Eli Lilly’s GLP-1 weight loss pill. The daily pill, called Foundayo, is the second oral GLP-1 product to reach the market over ...

Eli Lilly now has FDA approval for its GLP-1 obesity pill, introducing a convenient dosing alternative to injections and new competition to a Novo Nordisk weight loss pill that has experienced strong ...

The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive ...

The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for ...

April 1 (UPI) --The Food and Drug Administration on Wednesday approved Eli Lilly's pill version of a GLP-1 medication for weight loss, making it the second company to offer a non-injectable version of ...